Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCTC21C in Systemic Lupus Erythematosus
NCT07538154Phase 2Not yet recruiting
- Sponsor
- Sinocelltech Group Limited
- Start
- Apr 2026
- Primary completion
- Apr 2027
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of SCTC21C in systemic lupus erythematosus (SLE), sponsored by Sinocelltech Group Limited. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
SCTC21C
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT07538154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07538154.